한글목차

세계의 신경영양성 각막염 치료 시장 규모는 2019년 3억 1,369만 달러에 달했고 2024년까지 27.00% 이상의 CAGR을 나타냈습니다.

당뇨병의 높은 유병률

당뇨병의 높은 유병률은 과거의 기간에 신경영양성 각막염 치료 시장의 성장을 가속했습니다. 각막의 보호반사나 치유능력이 상실되어 궤양이나 감염증에 걸리기 쉬워지므로 신경영양성 각막염을 발병할 가능성이 높아집니다. 예를 들어, 벨기에에 본사를 둔 각국 당뇨병 협회의 산하 조직인 국제당뇨병연맹(IDF)에 따르면 2021년 전 세계 20-79세 성인 5억 3,700만 명이 당뇨병에 걸렸으며, 이 중 4분의 3 이상이 저소득 및 중간 소득 국가에 거주하고 있습니다. 이 질병으로 인해 약 670만 명이 사망했으며, 이는 5초마다 한 명씩 사망하는 것과 같습니다. 당뇨병과 관련된 의료비 지출은 9,660억 달러로 지난 15년 동안 316% 증가했습니다. 또한 5억 4,100만 명의 성인이 내당능 장애(IGT)를 앓고 있어 제2형 당뇨병 발병 위험이 높아졌습니다. 또한 미국 국가 공중 보건 기관인 질병통제예방센터(CDC)가 발표한 전국 당뇨병 통계 보고서에 따르면 2021년 미국 시민의 11.6%, 즉 모든 연령대의 3,840만 명이 당뇨병을 앓은 것으로 나타났습니다.

이 보고서는 세계의 신경영양성 각막염 치료 시장에 대한 조사 분석을 통해 시장 특징, 각 지역 시장 규모 및 예측, 경쟁 구도, 시장 기회 및 전략 등의 정보를 제공합니다.

목차

제1장 주요 요약

• 신경영양성 각막염 치료 - 시장의 매력과 거시경제 상황

제2장 목차

제3장 표 목록

제4장 그림 목록

제5장 보고서 구성

제6장 시장 특징

• 일반적인 시장의 정의
• 요약
• 신경영양성 각막염 치료 시장 정의와 세분화
• 시장 세분화 : 치료별
  • 국소 항생제
  • 재조합 인간 신경 성장 인자(rhNGF)
  • 양막 이식
  • 각막 성형술
  • 기타 치료
• 시장 세분화 : 투여 경로별
  • 구강
  • 국소
  • 기타 투여 경로
• 시장 세분화 : 최종 사용자별
  • 병원
  • 재택치료
  • 전문 클리닉
  • 기타 최종 사용자

제7장 주요 시장 동향

• 각막 조직편에 의한 원추 각막 치료의 혁신
• 수포성 각막증 환자에게 새로운 희망을 가져다주는 혁신적인 세포 요법
• 캐나다 최초의 프리로드 DMEK 이식이 실현되는 공동 연구

제8장 세계의 신경영양성 각막염 치료 성장 분석, 전략적 분석 프레임워크

• 신경영양성 각막염 치료의 PESTEL 분석
• 최종 이용 산업의 분석
  • 병원
  • 재택치료
  • 전문센터
  • 기타 최종 사용자
• 세계의 신경영양성 각막염 치료 시장 성장률 분석
• 시장 규모
• 시장 성장 실적(2019-2024년)
  • 시장 성장 촉진요인(2019-2024년)
  • 시장 성장 억제요인(2019-2024년)
• 시장 성장 예측(2024-2029년, 2034년)
  • 시장 성장 촉진요인(2024년-2029년)
  • 시장 성장 억제요인(2024년-2029년)
• 성장요인 예측
  • 양적 성장 요인
  • 성장 촉진요인
  • 성장 억제요인
• 세계의 신경영양성 각막염 치료 전체 시장(TAM)

제9장 세계의 신경영양성 각막염 치료 시장 세분화

• 세계의 신경영양성 각막염 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 국소 항생제별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 재조합 인간 신경 성장 인자(rhNGF)별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 양막 이식별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 각막 성형술별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 기타 치료별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)

제10장 신경영양성 각막염 치료 시장 : 지역과 국가의 분석

• 세계의 신경영양성 각막염 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2029년, 2034년)
• 세계의 신경영양성 각막염 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2029년, 2034년)

제11장 아시아태평양 시장

제12장 서유럽 시장

제13장 동유럽 시장

제14장 북미 시장

제15장 남미 시장

제16장 중동 시장

제17장 아프리카 시장

제18장 경쟁 구도와 기업 프로파일

• 기업 프로파일
• Dompe Farmaceutici SpA
• BRIM Biotechnology Inc.
• Recordati SpA
• Oyster Point Pharma Inc.
• HLB Therapeutics Co. Ltd.

제19장 기타 주요 기업과 혁신적 기업

• Neuroptika Inc.
• Aurolab
• ReGenTree LLC
• Claris Biotherapeutics Inc.
• Mime Tech
• RegeneRx Biopharmaceuticals

제20장 경쟁 벤치마킹

제21장 경쟁 대시보드

제22장 주요 인수합병(M&A)

• Bausch Lomb Acquired Novartis AG
• HLB Group Acquired RegeneRx Biopharmaceuticals Inc

제23장 기회와 전략

• 세계의 신경영양성 각막염 치료 시장 - 가장 새로운 기회를 제공하는 국가(2029년)
• 세계의 신경영양성 각막염 치료 시장 - 가장 새로운 기회를 제공하는 부문(2029년)
• 세계의 신경영양성 각막염 치료 시장 - 성장 전략(2029년)
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제24장 신경영양성 각막염 치료 시장 : 결론과 제안

• 결론
• 권고
  • 제품
  • 장소
  • 가격
  • 판촉
  • 사람들

제25장 부록

영문목차

Neurotrophic keratitis treatment refers to the therapies and medical interventions designed to manage and treat neurotrophic keratitis (NK), a rare degenerative disease of the cornea caused by impaired corneal nerve function. This condition leads to decreased or absent corneal sensation, resulting in impaired healing, persistent epithelial defects and corneal ulceration, which can progress to perforation in severe cases. comprises pharmaceutical drugs, surgical interventions and regenerative therapies aimed at restoring corneal integrity, preventing complications and improving patients' vision and quality of life.

The neurotrophic keratitis treatment market consists of sales of neurotrophic keratitis treatments and related services by entities (organizations, sole traders and partnerships) that develop and provide treatments to address the underlying nerve damage, promote corneal healing and prevent disease progression. The use of neurotrophic keratitis treatments depends on the severity of the disease, which is classified into three stages: early-stage epithelial irregularities (Stage I), persistent epithelial defects (Stage II) and corneal ulceration or perforation (Stage III).

The global neurotrophic keratitis treatment market was valued at $313.69 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 27.00%.

High Prevalence Of Diabetes

The high prevalence of diabetes drove the growth of the neurotrophic keratitis treatment market during the historic period. Chronic hyperglycemia in diabetic patients can lead to diabetic neuropathy, which affects the corneal nerves, impairing their ability to detect and respond to injuries. This increases the likelihood of developing neurotrophic keratitis, as the cornea loses its protective reflexes and healing capacity, making it more vulnerable to ulcers and infections. For example, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of national diabetes associations, diabetes affected 537 million adults aged 20-79 worldwide in 2021, with over three-quarters residing in low- and middle-income countries. The disease caused approximately 6.7 million deaths, equating to one death every five seconds. Health expenditures related to diabetes reached USD 966 billion, marking a 316% increase over the past 15 years. Further, 541 million adults had impaired glucose tolerance (IGT), heightening their risk of developing type 2 diabetes. Additionally, according to the National Diabetes Statistics Report published by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, 11.6% of US citizens or 38.4 million people of all ages, suffered from diabetes in 2021. With age, the percentage of people with diabetes rose and among those 65 years of age or older, it reached 29.2%. Therefore, the high prevalence of diabetes contributed to the growth of the neurotrophic keratitis treatment market.

Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments

Major companies operating in the neurotrophic keratitis treatment market are focusing on revolutionizing keratoconus treatment with contoured corneal tissue segments. By developing contoured corneal tissue segments, companies aim to improve the structural integrity of the cornea while also potentially promoting nerve regeneration and better healing. These segments can be precisely designed to match the patient's specific corneal anatomy, offering a personalized treatment approach that enhances both mechanical stability and sensory function. For instance, in June 2024, CorneaGen, a US-based developer of medical devices, launched the Corneal Tissue Addition for Keratoplasty (CTAK), a solution designed for corneal contouring in keratoconic eyes. CTAK provides patient-ready, gamma-irradiated, sterile, non-immunogenic corneal tissue segments, laser-cut and customized to the patient's specific cone severity and location. This advancement aims to improve surgical outcomes and make optimal use of corneal donations.

The global neurotrophic keratitis treatment market is highly concentrated, with large player dominating the market. The top 1 competitor in the market made up 100% of the total market in 2023.

Neurotrophic Keratitis Treatment Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global neurotrophic keratitis treatment market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for neurotrophic keratitis treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The neurotrophic keratitis treatment market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider neurotrophic keratitis treatment market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment, by route of administration and by end-user.
• Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment, by route of administration and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size and Growth - Regional market size forecast (2030-2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
• Competitive Dashboard - Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Recent Developments - Information on recent developments in the market covered in the report.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for neurotrophic keratitis treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (RhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
• 2) By Route Of Administration: Oral; Topical; Other Routes Of Administration
• 3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Companies Mentioned: Dompe Farmaceutici S.p.A.; BRIM Biotechnology Inc.; Recordati S.p.A; Oyster Point Pharma Inc.; HLB Therapeutics Co. Ltd.
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; neurotrophic keratitis treatment indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Neurotrophic Keratitis Treatment - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Neurotrophic Keratitis Treatment Market Definition And Segmentations
• 6.4 Market Segmentation By Treatment
  • 6.4.1 Topical Antibiotics
  • 6.4.2 Recombinant Human Nerve Growth Factor (rhNGF)
  • 6.4.3 Amniotic Membrane Transplantation
  • 6.4.4 Keratoplasty
  • 6.4.5 Other Treatments
• 6.5 Market Segmentation By Route of Administration
  • 6.5.1 Oral
  • 6.5.2 Topical
  • 6.5.3 Other Routes of Administration
• 6.6 Market Segmentation By End-User
  • 6.6.1 Hospitals
  • 6.6.2 Homecare
  • 6.6.3 Specialty Clinics
  • 6.6.4 Other End-Users

7 Major Market Trends

• 7.1 Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments
• 7.2 Innovative Cell Therapy Brings New Hope To Bullous Keratopathy Patients
• 7.3 Research Collaboration Leads to Canada's First Preloaded DMEK Transplant

8 Global Neurotrophic Keratitis Treatment Growth Analysis And Strategic Analysis Framework

• 8.1 Global Neurotrophic Keratitis Treatment PESTEL Analysis
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis Of End User Industries
  • 8.2.1 Hospitals
  • 8.2.2 Home Care
  • 8.2.3 Specialty Centers
  • 8.2.4 Other End Users
• 8.3 Global Neurotrophic Keratitis Treatment Market Growth Rate Analysis
• 8.4 Market Size
• 8.5 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 8.5.1 Market Drivers 2019 - 2024
  • 8.5.2 Market Restraints 2019 - 2024
• 8.6 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 8.6.1 Market Drivers 2024 - 2029
  • 8.6.2 Market Restraints 2024 - 2029
• 8.7 Forecast Growth Contributors/Factors
  • 8.7.1 Quantitative Growth Contributors
  • 8.7.2 Drivers
  • 8.7.3 Restraints
• 8.8 Global Neurotrophic Keratitis Treatment Total Addressable Market (TAM)

9 Global Neurotrophic Keratitis Treatment Market Segmentation

• 9.1 Global Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.2 Global Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.3 Global Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.4 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Topical Antibiotics, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.5 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Recombinant Human Nerve Growth Factor (rhNGF), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.6 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Amniotic Membrane Transplantation, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.7 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Keratoplasty, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 9.8 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Other Treatments, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Neurotrophic Keratitis Treatment Market, Regional and Country Analysis

• 10.1 Global Neurotrophic Keratitis Treatment Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Neurotrophic Keratitis Treatment Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.4 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.5 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.6 Asia-Pacific Neurotrophic Keratitis Treatment Market: Country Analysis
• 11.7 China Market
• 11.8 Summary
• 11.9 Market Overview
  • 11.9.1 Country Information
  • 11.9.2 Market Information
  • 11.9.3 Background Information
  • 11.9.4 Government Initiatives
  • 11.9.5 Regulations
  • 11.9.6 Regulatory Bodies
  • 11.9.7 Major Associations
  • 11.9.8 Taxes Levied
  • 11.9.9 Corporate Tax Structure
  • 11.9.10 Major Companies
• 11.10 China Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.11 China Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.12 China Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.13 India Market
• 11.14 India Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.15 India Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.16 India Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.17 Japan Market
• 11.18 Market Overview
  • 11.18.1 Country Information
  • 11.18.2 Market Information
  • 11.18.3 Background Information
  • 11.18.4 Government Initiatives
  • 11.18.5 Regulations
  • 11.18.6 Regulatory Bodies
  • 11.18.7 Major Associations
  • 11.18.8 Taxes Levied
  • 11.18.9 Corporate Tax Structure
  • 11.18.10 Investments
  • 11.18.11 Major Companies
• 11.19 Japan Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.20 Japan Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.21 Japan Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.22 Australia Market
• 11.23 Australia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.24 Australia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.25 Australia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.26 Indonesia Market
• 11.27 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.28 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.29 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.30 South Korea Market
• 11.31 Market Overview
  • 11.31.1 Country Information
  • 11.31.2 Market Information
  • 11.31.3 Background Information
  • 11.31.4 Government Initiatives
  • 11.31.5 Regulations
  • 11.31.6 Regulatory Bodies
  • 11.31.7 Major Associations
  • 11.31.8 Taxes Levied
  • 11.31.9 Corporate Tax Structure
  • 11.31.10 Investment
  • 11.31.11 Major Companies
• 11.32 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.33 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 11.34 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Western Europe Neurotrophic Keratitis Treatment Market: Country Analysis
• 12.7 UK Market
• 12.8 UK Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 UK Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 UK Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 Germany Market
• 12.12 Germany Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 Germany Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 Germany Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 France Market
• 12.16 France Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 France Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 France Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.19 Italy Market
• 12.20 Italy Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.21 Italy Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.22 Italy Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.23 Spain Market
• 12.24 Spain Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.25 Spain Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 12.26 Spain Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Major companies
• 13.3 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.6 Eastern Europe Neurotrophic Keratitis Treatment Market: Country Analysis
• 13.7 Russia Market
• 13.8 Russia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.9 Russia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 13.10 Russia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 North America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 North America Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 North America Neurotrophic Keratitis Treatment Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Investments
  • 14.9.11 Major Companies
• 14.10 USA Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.11 USA Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.12 USA Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.17 Canada Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 14.18 Canada Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.1 Market Overview
  • 15.1.1 Region Information
  • 15.1.2 Market Information
  • 15.1.3 Background Information
  • 15.1.4 Government Initiatives
  • 15.1.5 Regulations
  • 15.1.6 Regulatory Bodies
  • 15.1.7 Major Associations
  • 15.1.8 Taxes Levied
  • 15.1.9 Corporate Tax Structure
  • 15.1.10 Major Companies
• 15.2 South America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.3 South America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 South America Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 South America Neurotrophic Keratitis Treatment Market: Country Analysis
• 15.6 Brazil Market
• 15.7 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.8 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 15.9 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Major Companies
• 16.3 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Major Companies
• 17.3 Africa Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Africa Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Africa Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Dompe Farmaceutici S.p.A.
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Business Strategy
  • 18.2.4 Financial Overview
• 18.3 BRIM Biotechnology Inc.
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview
• 18.4 Recordati S.p.A.
  • 18.4.1 Company Overview
  • 18.4.2 Products And Services
  • 18.4.3 Financial Overview
• 18.5 Oyster Point Pharma Inc.
  • 18.5.1 Company Overview
  • 18.5.2 Products And Services
  • 18.5.3 Business Strategy
  • 18.5.4 Financial Overview
• 18.6 HLB Therapeutics Co. Ltd.
  • 18.6.1 Company Overview
  • 18.6.2 Products And Services
  • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

• 19.1 Neuroptika Inc.
  • 19.1.1 Company Overview
  • 19.1.2 Product And Services
• 19.2 Aurolab
  • 19.2.1 Company Overview
  • 19.2.2 Product And Services
• 19.3 ReGenTree LLC
  • 19.3.1 Company Overview
  • 19.3.2 Product And Services
• 19.4 Claris Biotherapeutics Inc.
  • 19.4.1 Company Overview
  • 19.4.2 Product And Services
• 19.5 Mime Tech
  • 19.5.1 Company Overview
  • 19.5.2 Product And Services
• 19.6 RegeneRx Biopharmaceuticals
  • 19.6.1 Company Overview
  • 19.6.2 Product And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Bausch + Lomb Acquired Novartis AG
• 22.2 HLB Group Acquired RegeneRx Biopharmaceuticals Inc

23 Opportunities And Strategies

• 23.1 Global Neurotrophic Keratitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 23.2 Global Neurotrophic Keratitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 23.3 Global Neurotrophic Keratitis Treatment Market In 2029 - Growth Strategies
  • 23.3.1 Market Trend Based Strategies
  • 23.3.2 Competitor Strategies

24 Neurotrophic Keratitis Treatment Market, Conclusions And Recommendations

• 24.1 Conclusions
• 24.2 Recommendations
  • 24.2.1 Product
  • 24.2.2 Place
  • 24.2.3 Price
  • 24.2.4 Promotion
  • 24.2.5 People

25 Appendix

• 25.1 Geographies Covered
• 25.2 Market Data Sources
• 25.3 Research Methodology
• 25.4 Currencies
• 25.5 The Business Research Company
• 25.6 Copyright and Disclaimer